Francesco Frasca

List of Publications by Citations

74 papers	6,582 citations	33 h-index	81 g-index
81 ext. papers	7,281 ext. citations	6.6 avg, IF	5.49 L-index

#	Paper	IF	Citations
74	Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. *Endocrine Reviews*, **2009**, 30, 586-623	27.2	730
73	Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. *Journal of Cancer Epidemiology*, **2013**, 2013, 965212	2.8	726
72	Diabetes and cancer. *Endocrine-Related Cancer*, **2009**, 16, 1103-23	5.7	707
71	Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Molecular and Cellular Biology*, **1999**, 19, 3278-88	4.8	697
70	Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. *Journal of Biological Chemistry*, **2002**, 277, 39684-95	5.4	342
69	The role of insulin receptors and IGF-I receptors in cancer and other diseases. *Archives of Physiology and Biochemistry*, **2008**, 114, 23-37	2.2	313
68	Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. *Oncogene*, **1999**, 18, 2471-9	9.2	236
67	BRAF(V600E) mutation and the biology of papillary thyroid cancer. *Endocrine-Related Cancer*, **2008**, 15, 191-205	5.7	183
66	Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. *Clinical Cancer Research*, **1999**, 5, 1935-44	12.9	177
65	Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. *PLoS ONE*, **2011**, 6, e22552	3.7	174
64	Insulin Receptor Isoforms in Physiology and Disease: An Updated View. *Endocrine Reviews*, **2017**, 38, 379-431	27.2	168
63	Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. *Cancer Research*, **2005**, 65, 1849-57	10.1	168
62	Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 766-74	5.6	114
61	Papillary thyroid cancer incidence in the volcanic area of Sicily. *Journal of the National Cancer Institute*, **2009**, 101, 1575-83	9.7	111
60	IGF and insulin receptor signaling in breast cancer. *Journal of Mammary Gland Biology and Neoplasia* , **2008**, 13, 381-406	2.4	99
59	Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. *Endocrinology*, **2006**, 147, 4463-75	4.8	88
58	Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. *Thyroid*, **2007**, 17, 1109-15	6.2	81

57	Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. *Cancer Research*, **2006**, 66, 4263-72	10.1	78
56	HMGA1 inhibits the function of p53 family members in thyroid cancer cells. *Cancer Research*, **2006**, 66, 2980-9	10.1	75
55	Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 808-15	4.5	67
54	Insulin receptors in breast cancer. *Annals of the New York Academy of Sciences*, **1996**, 784, 173-88	6.5	65
53	Modifications in the papillary thyroid cancer gene profile over the last 15 years. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E1758-65	5.6	59
52	p53 family proteins in thyroid cancer. *Endocrine-Related Cancer*, **2007**, 14, 43-60	5.7	57
51	Curcumin, Hormesis and the Nervous System. *Nutrients*, **2019**, 11,	6.7	55
50	Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. *Oncogene*, **2001**, 20, 3845-56	9.2	54
49	Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. *Breast Disease*, **2003**, 17, 73-89	1.6	52
48	Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. *Molecular Endocrinology*, **1996**, 10, 1318-26		51
47	Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. *Endocrinology*, **2004**, 145, 4355-65	4.8	41
46	Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. *International Journal of Cancer*, **2012**, 130, 2259-70	7.5	35
45	The p53-homologue p63 may promote thyroid cancer progression. *Endocrine-Related Cancer*, **2005**, 12, 953-71	5.7	34
44	p73 tumor-suppressor activity is impaired in human thyroid cancer. *Cancer Research*, **2003**, 63, 5829-37	10.1	34
43	17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells. *Cancer Research*, **2007**, 67, 8932-41	10.1	33
42	Levels of histone acetylation in thyroid tumors. *Biochemical and Biophysical Research Communications*, **2011**, 411, 679-83	3.4	32
41	Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. *Journal of Pathology*, **2009**, 218, 66-75	9.4	31
40	DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. *International Journal of Cancer*, **2009**, 124, 2539-48	7.5	30

39	Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. *Molecular Endocrinology*, **1996**, 10, 1318-1326		30
38	Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. *Frontiers in Endocrinology*, **2017**, 8, 312	5.7	29
37	Update on thyroid cancer treatment. *Future Oncology*, **2012**, 8, 1331-48	3.6	29
36	Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 2880-9	5.6	28
35	Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. *Journal of Biological Chemistry*, **2007**, 282, 26077-88	5.4	27
34	The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. *Thyroid*, **2014**, 24, 1267-74	6.2	26
33	Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway. *Journal of Cellular Biochemistry*, **1998**, 70, 268-80	4.7	24
32	IRF5 promotes the proliferation of human thyroid cancer cells. *Molecular Cancer*, **2012**, 11, 21	42.1	23
31	Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. *Journal of Biological Chemistry*, **2003**, 278, 25151-7	5.4	23
30	Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E1168-78	5.6	22
29	TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. *Molecular Cancer Research*, **2008**, 6, 64-77	6.6	20
28	Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. *Clinical Endocrinology*, **2016**, 84, 614-9	3.4	20
27	c-Abl and insulin receptor signalling. *Vitamins and Hormones*, **2009**, 80, 77-105	2.5	19
26	The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. *Journal of Endocrinological Investigation*, **2013**, 36, 249-54	5.2	18
25	Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells. *Bioinformatics*, **2019**, 35, 2267-2275	7.2	18
24	Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity. *Endocrinology*, **1996**, 137, 4100-7	4.8	17
23	Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2502-12	5.6	15
22	Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells. *Anticancer Research*, **2018**, 38, 6653-6662	2.3	15

21	Seasonal variations in TSH serum levels in athyreotic patients under L-thyroxine replacement monotherapy. *Clinical Endocrinology*, **2017**, 87, 207-215	3.4	14
20	In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. *Cellular Oncology (Dordrecht)*, **2011**, 34, 131-40	7.2	14
19	Selenium exerts protective effects against oxidative stress and cell damage in human thyrocytes and fibroblasts. *Endocrine*, **2020**, 68, 151-162	4	14
18	Relationship between betacoronaviruses and the endocrine system: a new key to understand the COVID-19 pandemic-A comprehensive review. *Journal of Endocrinological Investigation*, **2021**, 44, 1553-1570	5.2	14
17	Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway. *Annals of the New York Academy of Sciences*, **2009**, 1155, 263-7	6.5	13
16	Expression of neurotrophins, GDNF, and their receptors in rat thyroid tissue. *Cell and Tissue Research*, **1999**, 295, 467-75	4.2	8
15	The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer. *Cancers*, **2020**, 12,	6.6	8
14	Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend. *Journal of Endocrinological Investigation*, **2019**, 42, 1223-1230	5.2	7
13	Role of selenium and myo-inositol supplementation on autoimmune thyroiditis progression. *Endocrine Journal*, **2020**, 67, 1093-1098	2.9	7
12	Challenges in the treatment of parathyroid carcinoma: a case report. *Hormones*, **2019**, 18, 325-328	3.1	6
11	Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids. *Frontiers in Endocrinology*, **2020**, 11, 609895	5.7	5
10	Abnormal 1-hour post-load glycemia during pregnancy impairs post-partum metabolic status: a single-center experience. *Journal of Endocrinological Investigation*, **2018**, 41, 567-573	5.2	4
9	Cytological diagnosis difficulties in hyalinizing trabecular adenoma of the thyroid. *Journal of Endocrinological Investigation*, **2011**, 34, 887-8	5.2	4
8	Re: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. *Journal of the National Cancer Institute*, **2009**, 101, 1030-1; author reply 1031-2	9.7	4
7	Thyroid Cancer and Circadian Clock Disruption. *Cancers*, **2020**, 12,	6.6	4
6	Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism. *Frontiers in Endocrinology*, **2020**, 11, 367	5.7	2
5	Recent insights into the pathogenesis of autoimmune hypophysitis. *Expert Review of Clinical Immunology*, **2021**, 17, 1175-1185	5.1	2
4	Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis. *Hormones*, **2021**, 20, 161-165	3.1	1

3	Validit dei sistemi di classificazione ecografica nell dentificare i noduli tiroidei da non sottoporre all goaspirato. *L Endocrinologo*, **2020**, 21, 108-114	o
2	Endocrinopatie e anemie / anemie ed endocrinopatie: una si(pali)ndrome spesso misconosciuta. *L Endocrinologo*, **2020**, 21, 277-283	o
1	Il ruolo della tireoglobulina ultrasensibile nel follow-up del carcinoma differenziato tiroideo. *L Endocrinologo*, **2020**, 21, 64-66	o